MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
Key Details
- 1AI tools are advancing early detection in medical imaging, including lymph node metastases previously missed by standard diagnostics.
- 2Proton therapy is becoming more widespread, with phase III trials (e.g., 440 oropharyngeal cancer patients) showing reduced toxicities versus traditional radiation.
- 3Biomarker research is personalizing prostate cancer care, such as the NRG GU006 trial using genomic tools.
- 4Theranostics and radiopharmaceuticals, like FDA-approved Pluvicto, are expanding from localized to systemic radiation treatments.
- 5MD Anderson researchers are presenting over 65 abstracts at ASTRO covering these innovations.
Why It Matters
AI's integration into medical imaging is quickly improving diagnostic accuracy and treatment personalization in oncology. These advances—especially in clinical trials and real-world applications—are set to directly impact radiology workflows and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI-Powered OCT Enables Rapid 'Optical Biopsy' for Early Endometrial Cancer Detection
A team at Washington University has developed a catheter-based 3D OCT system with AI to quickly and noninvasively detect early endometrial cancers.
•EurekAlert
AI Clinical Reasoning in Diagnostics and Digital Fatigue in Healthcare
Recent JMIR features explore large language models in clinical diagnostics and digital fatigue among healthcare professionals.
•EurekAlert
AI Method Protects Sensitive Data in ECGs While Retaining Clinical Value
Researchers developed an AI model (PP-VAE) that safeguards sensitive personal data in electrocardiograms without sacrificing clinical utility.